Lipophilic nanoparticles for drug delivery
First Claim
Patent Images
1. A structure comprising:
- a nanostructure core comprising an inorganic material;
a shell comprising a lipid layer surrounding and attached to the nanostructure core, the shell having an inner surface and an outer surface, wherein the shell has a therapeutic profile for a therapeutic agent, wherein the therapeutic agent is attached to the shell,wherein the therapeutic profile is modified to regulate the binding capacity and/or the binding affinity between the therapeutic agent and the nanostructure;
a protein bound to at least the outer surface of the shell,wherein at least 80% of the lipids in the outer surface of the shell have negatively charged head groups, and wherein 20-400 therapeutic agents are associated per structure; and
wherein the inner surface of the shell comprises PDP PE 16;
0 or PDP PE 18;
1.
2 Assignments
0 Petitions
Accused Products
Abstract
Nanostructures having a core, a lipid layer and a lipoprotein which are useful for delivering therapeutic agents are provided herein. Methods of treating disease using the nanostructures are also provided, including methods of treating cancer, infectious disease, vascular disease etc.
64 Citations
19 Claims
-
1. A structure comprising:
-
a nanostructure core comprising an inorganic material; a shell comprising a lipid layer surrounding and attached to the nanostructure core, the shell having an inner surface and an outer surface, wherein the shell has a therapeutic profile for a therapeutic agent, wherein the therapeutic agent is attached to the shell, wherein the therapeutic profile is modified to regulate the binding capacity and/or the binding affinity between the therapeutic agent and the nanostructure; a protein bound to at least the outer surface of the shell, wherein at least 80% of the lipids in the outer surface of the shell have negatively charged head groups, and wherein 20-400 therapeutic agents are associated per structure; and wherein the inner surface of the shell comprises PDP PE 16;
0 or PDP PE 18;
1. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16, 17, 18, 19)
-
-
14. A structure comprising:
-
a nanostructure core comprising an inorganic material; a shell comprising a lipid layer surrounding and attached to the nanostructure core, the shell having an inner surface and an outer surface; an apolipoprotein bound to at least the outer surface of the shell; and a therapeutic agent adsorbed on the outer shell and/or incorporated between the inner surface and outer surface of the shell, wherein the therapeutic agent is selected from the group consisting of andrographolide and vincristine, wherein at least 80% of the lipids in the outer surface of the shell have negatively charged head groups.
-
-
15. A method of treating a disease with reduced toxicity, comprising
administering to a subject having a disease a nanostructure comprising a core, a shell comprising a lipid layer surrounding and attached to the core, the shell having an inner surface and an outer surface; - an apolipoprotein associated with the shell and a therapeutic agent having toxic properties in order to treat the disease, while causing less toxicity than the toxicity caused by treatment of a subject having the disease with the therapeutic agent alone,
wherein the disease is a cancer that expresses scavenger receptor type B-, wherein toxicity is cardiotoxicity, wherein 20-400 therapeutic agents are associated per structure, and wherein the inner surface of the shell comprises PDP PE 16;
0 or PDP PE 18;
1.
- an apolipoprotein associated with the shell and a therapeutic agent having toxic properties in order to treat the disease, while causing less toxicity than the toxicity caused by treatment of a subject having the disease with the therapeutic agent alone,
Specification